1. Home
  2. GMRE vs TRML Comparison

GMRE vs TRML Comparison

Compare GMRE & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GMRE
  • TRML
  • Stock Information
  • Founded
  • GMRE 2011
  • TRML 2021
  • Country
  • GMRE United States
  • TRML United States
  • Employees
  • GMRE N/A
  • TRML N/A
  • Industry
  • GMRE Real Estate Investment Trusts
  • TRML Biotechnology: Pharmaceutical Preparations
  • Sector
  • GMRE Real Estate
  • TRML Health Care
  • Exchange
  • GMRE Nasdaq
  • TRML Nasdaq
  • Market Cap
  • GMRE 508.9M
  • TRML 598.9M
  • IPO Year
  • GMRE N/A
  • TRML N/A
  • Fundamental
  • Price
  • GMRE $7.66
  • TRML $47.68
  • Analyst Decision
  • GMRE Buy
  • TRML Hold
  • Analyst Count
  • GMRE 3
  • TRML 11
  • Target Price
  • GMRE $10.38
  • TRML $46.95
  • AVG Volume (30 Days)
  • GMRE 691.1K
  • TRML 1.6M
  • Earning Date
  • GMRE 11-05-2025
  • TRML 11-06-2025
  • Dividend Yield
  • GMRE 7.85%
  • TRML N/A
  • EPS Growth
  • GMRE N/A
  • TRML N/A
  • EPS
  • GMRE 0.07
  • TRML N/A
  • Revenue
  • GMRE $141,896,000.00
  • TRML N/A
  • Revenue This Year
  • GMRE $7.69
  • TRML N/A
  • Revenue Next Year
  • GMRE $4.04
  • TRML N/A
  • P/E Ratio
  • GMRE $113.85
  • TRML N/A
  • Revenue Growth
  • GMRE 2.95
  • TRML N/A
  • 52 Week Low
  • GMRE $6.06
  • TRML $11.56
  • 52 Week High
  • GMRE $10.46
  • TRML $47.69
  • Technical
  • Relative Strength Index (RSI)
  • GMRE 65.26
  • TRML 94.40
  • Support Level
  • GMRE $7.26
  • TRML $22.31
  • Resistance Level
  • GMRE $7.73
  • TRML $47.69
  • Average True Range (ATR)
  • GMRE 0.14
  • TRML 1.21
  • MACD
  • GMRE 0.02
  • TRML 2.70
  • Stochastic Oscillator
  • GMRE 84.95
  • TRML 99.80

About GMRE Global Medical REIT Inc.

Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.

About TRML Tourmaline Bio Inc.

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

Share on Social Networks: